This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

3 Nov 2021

Lonza boosts exosome capability with Codiak BioSciences facility acquisition

The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies

In line with its strategy to advance the rapidly emerging specialty of exosome technology, Lonza has announced its acquisition of an exosome manufacturing facility located in Lexington, Massachusetts (US) from Codiak BioSciences.

As part of the deal Codiak — a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics — will receive approximately $65 million of “in kind” manufacturing services for its clinical-stage programmes. It will also retain its pipeline of therapeutic candidates as well as its exosome engineering and drug-loading technologies.

Lonza on the other hand will gain worldwide access and sub-licensable rights to Codiak's high-throughput perfusion-based process for exosome manufacturing.

Together, the companies plan to establish a Centre of Excellence that will leverage the strengths of both to advance developments in exosome production, purification and analytics. The centre will also provide Lonza customers with exosome assay and process development, analytics and manufacturing services.

According to Alberto Santagostino, SVP, Head of Cell and Gene Technologies at Lonza, exosomes could become the “next frontier in biotherapeutics”.

Mentioned Companies
View company profile

Related News